Technology showcase: BioCentury’s 2020 class of emerging companies

As emerging therapeutic modalities move toward mainstream, a flood of new companies has arisen to break through the limitations of first-generation technologies and expand the reach of gene and cell therapies, gene editing technologies, protein degraders and more across a wider swath of diseases. 

BioCentury profiled 119 start-ups in 2020, providing a snapshot of where innovators and investors are driving biotech’s leading edge...